Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133326 | 0.87 | TSHR (0.45) | ALDH1A1CYP3A4L3MBTL1TSHRGAA | |
| SCHEMBL14136630 | 0.81 | CYP3A4 (0.36) | ALDH1A1CYP3A4L3MBTL1TSHRGAA | |
| Phosphoric Acid SCHEMBL7044382 | 0.80 | TSHR (0.39) | ALDH1A1CYP3A4L3MBTL1TSHRGAA | |
| SCHEMBL837779 | 0.79 | ALDH1A1 (0.56) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL6866308 | 0.78 | CYP3A4 (0.33) | ALDH1A1CYP3A4L3MBTL1TSHRGAA | |
| SCHEMBL3823280 | 0.78 | TSHR (0.65) | ALDH1A1CYP3A4L3MBTL1TSHRGAA | |
| SCHEMBL1296634 | 0.78 | TSHR (0.65) | ALDH1A1CYP3A4L3MBTL1TSHRGAA | |
| SCHEMBL7306118 | 0.78 | CYP3A4 (0.33) | ALDH1A1CYP3A4L3MBTL1TSHRGAA | |
| SCHEMBL3630561 | 0.77 | ALDH1A1 (0.36) | ALDH1A1CYP3A4L3MBTL1TSHRGAA | |
| SCHEMBL2779785 | 0.77 | ALDH1A1 (0.32) | ALDH1A1CYP3A4L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| US-11191747-B2 | Pyrrole compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-11180518-B2 | Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-11-23 | — | — | US | disclosed |
| US-20210221833-A1 | PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PARAFFIN EMBEDDED TISSUE USING CAGED HAPTENS | VENTANA MED SYST INC (US) | 2021-07-22 | — | — | US | disclosed |
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2021-01-28 | — | — | US | disclosed |
| US-10604541-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-31 | — | — | US | disclosed |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190233449-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | US | disclosed |
| US-10308671-B2 | Water-soluble derivatives of 3,5-diphenyl-diazole compounds | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG (DE) | 2019-06-04 | — | — | US | disclosed |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-05-23 | — | — | US | disclosed |
| WO-2019003148-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
| US-9629840-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| US-20150202205-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2015-07-23 | — | — | US | disclosed |
| WO-2013066684-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604541-B2 | Glucokinase activators and methods of using same | GCK, GCKR, GALK1 | ALDH1A1 1524/4885CYP3A4 1580/4885L3MBTL1 2873/4885 |
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | HNRNPH1, HNRNPH3, HNRNPUL2 | ALDH1A1 3412/4885CYP3A4 4709/4885L3MBTL1 137/4885 |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | ALDH1A1 2620/4885CYP3A4 1050/4885L3MBTL1 2809/4885 |
| US-20230227437-A1 | IMMUNOMODULATOR | IL17A, IL2, IL2RA | ALDH1A1 261/4885CYP3A4 826/4885L3MBTL1 4577/4885 |
| US-10308671-B2 | Water-soluble derivatives of 3,5-diphenyl-diazole compounds | PARK7, PRNP, PDCD5 | ALDH1A1 1384/4885CYP3A4 545/4885L3MBTL1 935/4885 |
| US-20210221833-A1 | PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PARAFFIN EMBEDDED TISSUE USING CAGED HAPTENS | CD2BP2, CD68, CKAP4 | ALDH1A1 2355/4885CYP3A4 4502/4885L3MBTL1 1817/4885 |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | HNRNPH1, HNRNPH3, HNRNPUL2 | ALDH1A1 3412/4885CYP3A4 4709/4885L3MBTL1 137/4885 |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | ALDH1A1 2620/4885CYP3A4 1050/4885L3MBTL1 2809/4885 |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | ALDH1A1 3392/4885CYP3A4 1334/4885L3MBTL1 825/4885 |
| US-11858918-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | ALDH1A1 3556/4885CYP3A4 4535/4885L3MBTL1 2918/4885 |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | CCR5, ZC3HAV1L, CCRL2 | ALDH1A1 3257/4885CYP3A4 1322/4885L3MBTL1 884/4885 |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | ALDH1A1 3257/4885CYP3A4 1322/4885L3MBTL1 884/4885 |
| US-20190233449-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCK, GCKR, GALK1 | ALDH1A1 1524/4885CYP3A4 1580/4885L3MBTL1 2873/4885 |
| US-11191747-B2 | Pyrrole compounds | PKD1, ADCYAP1R1, PYCR1 | ALDH1A1 538/4885CYP3A4 439/4885L3MBTL1 4785/4885 |
| US-11180518-B2 | Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma | TYR, MITF, VHL | ALDH1A1 32/4885CYP3A4 1331/4885L3MBTL1 2537/4885 |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | ALDH1A1 1718/4885CYP3A4 1064/4885L3MBTL1 1303/4885 |
| US-20150202205-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | PIM1, PIM2, PIM3 | ALDH1A1 2942/4885CYP3A4 2602/4885L3MBTL1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.